Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics Inc (NQ: AKRO )

40.30 +1.98 (+5.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 492,851
Open 38.46
Bid (Size) 38.91 (1)
Ask (Size) 41.57 (1)
Prev. Close 38.32
Today's Range 38.11 - 40.40
52wk Range 7.520 - 54.88
Shares Outstanding 46,970,989
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
From Akero Therapeutics
Via Globe NewsWire
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
The battle pits 89bio and Akero in nonalcoholic steatohepatitis. 
Via Investor's Business Daily

Performance

YTD
-18.57%
-18.57%
1 Month
-8.26%
-8.26%
3 Month
-18.95%
-18.95%
6 Month
+51.22%
+51.22%
1 Year
+175.65%
+175.65%

More News

Read More
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Akero Therapeutics
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
Recap: Akero Therapeutics Q3 Earnings
Via Benzinga
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
From Akero Therapeutics
Via Globe NewsWire
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics
Via Globe NewsWire
20 Favorite Biotech & Medical Stocks For 2023
Via Talk Markets
Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program
Via Benzinga
Thanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise
Via Benzinga
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
From Akero Therapeutics
Via Globe NewsWire
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
From Akero Therapeutics
Via Globe NewsWire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
From Akero Therapeutics
Via Globe NewsWire
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
From Akero Therapeutics
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Akero Therapeutics
Via Globe NewsWire
Biotech Stocks Well-Positioned For The Fourth Quarter
Via Talk Markets
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
From Akero Therapeutics
Via Globe NewsWire
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Via Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
Via Benzinga
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.